Search Site

Ran Reshef, MD

  • Associate Professor of Medicine at CUMC
  • Director, Translational Research, Blood and Marrow Transplantation
  • Clinical Lead, CAR-T Cell Program
Ran Reshef, MD

Dr. Reshef trained in Hematology, Oncology and Bone Marrow Transplantation and received a Master of Science degree in Translational Research from the University of Pennsylvania. He joined Columbia University in 2015 as Director of Translational Research for the Blood and Marrow Transplantation program. He is the Clinical Lead for the CAR-T Cell Program at Columbia, a principal investigator at the Columbia Center for Translational Immunology and a member of the Herbert Irving Comprehensive Cancer Center.

The Reshef lab combines efforts in both basic research and clinical investigation to advance the understanding of immune responses following hematopoietic stem-cell transplantation and other forms of cell therapy.

The lab is focused on two primary areas:

1. Investigating lymphocyte migration mechanisms and how they affect the clinical and immunologic outcomes of stem-cell transplantation. The lab pioneered the use of chemokine receptor blockade after allogeneic stem-cell transplantation to reduce immune-mediated complications. 

2. Developing methodologies for the study of human samples from transplant recipients at the single-cell level in order to unravel novel immunologic mechanisms that would lead to new therapeutic approaches. The lab works with blood, stool and tissue samples and uses a diverse toolset that includes genomic and immunophenotypic methods to identify new therapeutic modalities. Our ultimate goal is to identify new targets that improve transplant outcomes using evidence in both mice and humans and to test these targets clinically. 

Dr. Reshef’s research is funded by the National Cancer Institute, Conquer Cancer Foundation, National Marrow Donor Program and Department of Defense. He previously received awards from the Leukemia & Lymphoma Society and the American Society of Hematology.

Departments and Divisions

  • Department of Medicine
    Division of Hematology/Oncology

Languages Spoken

  • Hebrew

Education & Training

  • MD, Medicine, Sackler School of Medicine, Tel Aviv University (Israel)
  • MSc, Translational Research, Perelman School of Medicine University of Pennsylvania
  • Internship: Tel Aviv Sourasky Medical Center, Israel
  • Residency: Tel Aviv Sourasky Medical Center, Israel
  • Fellowship: Perelman School of Medicine University of Pennsylvania

Lab Locations

  • William Black Building

    650 West 168th Street
    1516
    New York, NY 10032
    Phone:
    (212) 342 0530
    Lab Phone:
    (212) 305-6821
    Email:
    ran.reshef@columbia.edu

Presentations

CAR-T Cells Meet Myeloma - Myeloma Crowd NY May 2018

CAR T-Cell Therapy: What We Know (and Don’t Know) 1 Year Later - Association of American Cancer Centers

Committees / Societies / Memberships

American Society of Clinical Oncology 

American Society of Hematology 

American Society of Blood and Marrow Transplantation 

Center for International Blood and Marrow Transplant Research 

Bone Marrow Transplant Clinical Trials Network Steering Committee

Mount Sinai Acute GvHD International Consortium 

American Journal of Hematology (Editorial Board)

National Institues of Health (Study Section)

Department of Defense (Study Section)

Honors & Awards

  • Sternberg Research Award, Abramson Cancer Center, University of Pennsylvania (2008)
  • Bradley Fellow Research Award, Department of Medicine, University of Pennsylvania (2011)
  • Austrian Junior Faculty Award, Department of Medicine, University of Pennsylvania (2012)
  • Amy Strelzer Manasevit Award for the Study of Post-Transplant Complications, National Marrow Donor Program (2013)

NIH Grants

  • A PHASE 2 MULTICENTER STUDY OF AXICABTAGENE CILOLEUCEL IN SUBJECTS WITH RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA (INHL) (P&S Industry Clinical Trial)

    Sep 26 2018 - Sep 26 2023

    A PHASE III, RANDOMIZED, OPEN-LABEL, MULTI-CENTER STUDY OF RUXOLITINIB VERSUS BEST AVAILABLE THERAPYIN PATIENTS WITH CORTICOSTEROID-REFACTORY CHRONIC GRAFT VERSUS HOST DISEASE AFTER ALLOGENIC STEM CELL TRANSPLANTATION (P&S Industry Clinical Trial)

    May 30 2018 - May 30 2023

    A PHASE 3, MULTICENTER, RANDOMIZED, DBL-BLIND, DOUBLE-DUMMY, ACTIVE-CONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF MARIBAVIRCOMPARED TO VALGANCICLOVIR FOR TREATMENT OF CYTOMEGALOVIRUS(CMV) INFECTION IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS (P&S Industry Clinical Trial)

    Jun 16 2017 - Jun 16 2022

    A RANDOMIZED, DOUBLE-BLIND PHASE 3 STUDY OF IBRUTINIB IN COMBINATION WITH CORTICOSTEROIDS VERSUS PLACEBO IN COMBINATION WITH CORTICOSTEROIDS IN SUBJECTS WITH NEW ONSET CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD) (P&S Industry Clinical Trial)

    Apr 19 2017 - Apr 19 2022

    MULTICENTER, OPEN LABEL, PHASE 3 TRIAL OF ALLOGENEIC EPSTEIN-BARR VIRUS CYTOTOXIC T LYMPHOCYTES (EBV-CTLS) SOLID ORGAN TRANSPLANT PATIENTS W/ EBV-ASSOCIATED POST TRANSPLANT LYMPHOPROLIFERATIVE DISEASE AFTER FAILURE OF RITUXIMAB/RITUXIMAB & CHEMOTHERAPY (P&S Industry Clinical Trial)

    Apr 3 2017 - Apr 3 2022

    IL-33 BLOCKADE AS A NOVEL THERAPEUTIC FOR T-CELL MEDIATIATED HYPERCYTOKINEMIA SYNDROMES (Federal Gov)

    Jun 8 2016 - May 31 2021

    IDENTIFICATION OF EFFECTOR AND SUPPRESSIVE T-CELL CLONES IN GRAFT-VS-HOST DISEASE (Federal Gov)

    Jul 1 2018 - Jun 30 2020

    EZH2-MEDIATED EPIGENETIC EFFECTS AND ALLOIMMUNITY (Federal Gov)

    Jan 1 2016 - Dec 31 2019

    ROLE OF MICROBIOME DIVERSITY IN SHAPING THE GRAFT-VERSUS-HOST IMMUNE RESPONSE AFTER ALLOGENEIC HEMATOPOIETIC STEM-CELL TRANSPLANTATION (Private)

    Jun 1 2017 - May 31 2018

    A MULTI-CENTER PHASE LL TRIAL RANDOMIZING NOVEL APPROACHES FOR GRAFT-VERSUS-HOST DISEASE PREVENTION COMPARED TO CONTEMPORARY CONTROLS BMT CTN PROTOCOL#1203 (THE (Federal Gov)

    Oct 5 2015 - Oct 4 2017

    LYMPHOCYTE TRAFFICKING BLOCKADE IN ALLOGENEIC STEM-CELL TRANSPLANTATION (Federal Gov)

    Sep 12 2013 - Aug 31 2017

    CHEMOKINE RECEPTOR SIGNATURES IN ALLOGENEIC STEM CELL TRANSPLANTATION (Federal Gov)

    Aug 1 2013 - Jul 31 2016

    ASCO SEPARATING THE GVH AND GVT RESPONSES BY BLOCKING LYMPHOCYTE CHEMOTAXIS (Private)

    Jul 1 2015 - Jun 30 2016

    ASM: CONTROL OF HUMAN GRAFT-VERSUS-HOST DISEASE BY MODULATION OF LYMPHOCYTE TRAFFICKING (Private)

    Jul 1 2013 - Jun 30 2016

Lab Members

  • Rodney Macedo Gonzales, MD, PhD, Postdoctoral Researcher
  • Ximi Kevin Wang, Lab Technician
  • David Harle, Lab Technician
  • Christian Gordillo, Clinical Research Coordinator
  • Alexandra Matschiner, Medical Student

Publications

  1. Reshef R, Luger SM, Hexner EO, Loren AW, Frey NV, Nasta, SD, Goldstein SC, Stadtmauer EA, Smith J, Bailey S, Mick R, Heitjan DF, Emerson SG, Hoxie J, Vonderheide RH, Porter DL (2012). “Effect of Blocking Lymphocyte Chemotaxis on Visceral Graft-vs-Host Disease.” N Engl J Med 367:135-145
  2. Reshef R, Huffman AP, Gao A, Luskin MR, Hexner EO, Loren AW, Frey NV, Stadtmauer EA, Luger SM, Mangan JK, Nasta SD, Gill SI, Sell M, Kambayashi T, Richman LP, Vonderheide RH, Mick R, Porter DL (2015). “High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection In Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning” J Clin Oncol 33:2392-2398.
  3. Ryan H. Moy, Austin P. Huffman, Lee P. Richman, Lisa Crisalli, Ximi K. Wang, James A. Hoxie, Rosemarie Mick, Stephen G. Emerson, Yi Zhang, Robert H. Vonderheide, David L. Porter and Ran Reshef (2017) "Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis" Blood 129:906-916
  4. Mishkin AD, Mapara MY, Reshef R (2018). “Iatrogenic Infertility After Curative Stem Cell Transplantation in Sickle Cell Disease Patients”. Ann Intern Med 2018 Jun 19;168(12):881-88

For a complete list of publications, please visit PubMed.gov